Aktuelle News
News Funktionen
Weitere Funktionen
30 Juni 2015
Zealand Pharma A/S
Zealand announces total number of shares and voting rights in the company as of 30 June 2015
26 Juni 2015
Zealand Pharma A/S
Phase I trial results for Zealand’s glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy
23 Juni 2015
Zealand Pharma A/S
Major shareholder announcement
22 Juni 2015
Zealand Pharma A/S
Zealand announces an amendment to its Articles of Association to reflect an increase in share capital after exercise of employee warrants
20 Juni 2015
Zealand Pharma A/S
Zealand increases its share capital after exercise of employee warrants
12 Juni 2015
Zealand Pharma A/S
Major shareholder announcement
9 Juni 2015
Zealand Pharma A/S
Zealand informs of updates given by Sanofi on Lyxumia® and LixiLan on an IR Thematic Conference Call on Diabetes
8 Juni 2015
Zealand Pharma A/S
Zealand informs that data presented from the ELIXA study establish Lyxumia® as the first GLP-1 receptor agonist with cardiovascular safety proven in a long-term outcome trial
6 Juni 2015
Zealand Pharma A/S
Presentations on two novel Zealand preclinical peptide therapeutics as possible approaches for the treatment of Type 2 diabetes and obesity at the American Diabetes Association’s (ADA) 74th Scientific Sessions
Zealand Pharma A/S
Zealand announces that Sanofi has informed of results from GetGoal Duo-2, showing advantages of Lyxumia® versus rapid-acting insulin as add-on to Lantus® for the treatment of Type 2 diabetes
2 Juni 2015
Zealand Pharma A/S
Zealand increases the share capital after exercise of employee warrants and announces an amendment to its Articles of Association
Zealand Pharma A/S
New data on lixisenatide (Lyxumia®) including ELIXA results on LixiLan, and on novel Zealand peptide therapeutics, to be presented at the American Diabetes Association’s (ADA) 75th Scientific Sessions
29 Mai 2015
Zealand Pharma A/S
Zealand presents to investors at four conferences in June 2015
22 Mai 2015
Zealand Pharma A/S
Zealand Interim Report for Q1 2015 (unaudited) Increase in royalty revenue and progression of the development pipeline
20 Mai 2015
Zealand Pharma A/S
Zealand starts clinical development of a multiple-dose version of its stable glucagon analogue, ZP4207
13 Mai 2015
Zealand Pharma A/S
Notice of Zealand’s Interim Report for Q1 2015 and related conference call
Zealand Pharma A/S
Zealand announces an amendment to its Articles of Association following grant of warrants
5 Mai 2015
Zealand Pharma A/S
Zealand announces grants of new warrants under employee warrant programs and reports of transactions in the company’s shares and related securities by managerial employees and their related parties
4 Mai 2015
Zealand Pharma A/S
Zealand gives three presentations at the American TIDES 2015 conference – including as keynote speaker
30 April 2015
Zealand Pharma A/S
Zealand announces total number of shares and voting rights in the company as of 30 April 2015
Zealand Pharma A/S
Zealand reports Lyxumia® royalty revenue for Q1 2015
22 April 2015
Zealand Pharma A/S
Major shareholder announcement
21 April 2015
Zealand Pharma A/S
Passing of Zealand’s Annual General Meeting in 2015
13 April 2015
Zealand Pharma A/S
Zealand announces an amendment to its Articles of Association to reflect an increase in share capital after exercise of employee warrants
11 April 2015
Zealand Pharma A/S
Zealand increases the share capital after exercise of employee warrants
26 März 2015
Zealand Pharma A/S
Zealand convenes for the Annual General Meeting 2015
25 März 2015
Zealand Pharma A/S
Zealand announces an amendment to its Articles of Association to reflect grant of warrants
Zealand Pharma A/S
Zealand announces the grant of warrants under existing warrant scheme
24 März 2015
Zealand Pharma A/S
CORRECTION: Zealand announces an amendment to its Articles of Association to reflect an increase in share capital after exercise of employee warrants
Zealand Pharma A/S
Zealand announces an amendment to its Articles of Association to reflect an increase in share capital after exercise of employee warrants